Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.
Manoj K Doss, Michal Považan, Monica D Rosenberg, Nathan D Sepeda, Alan K Davis, Patrick H Finan, Gwenn S Smith, James J Pekar, Peter B Barker, Roland R Griffiths, Frederick S Barrett
Translational psychiatry November 8, 2021 DOI: 10.1038/s41398-021-01706-y via PubMed
Summary
AI-generated from the abstractPsilocybin therapy increased cognitive flexibility for at least four weeks in 24 patients with major depressive disorder, though these improvements were not linked to antidepressant effects. One week after treatment, glutamate and N-acetylaspartate concentrations decreased in the anterior cingulate cortex (ACC), and functional connectivity dynamics increased between the ACC and posterior cingulate cortex. Surprisingly, larger increases in this neural flexibility were associated with smaller gains in cognitive flexibility. Baseline brain connectivity from the ACC predicted cognitive flexibility improvements, with greater baseline connectivity linked to better baseline flexibility but less improvement. The findings suggest that while some increase in neural dynamics may help shift from rigid states, larger persisting increases may be less beneficial.
Study at a glance
| Characteristics | Open-label study Peer reviewed |
|---|---|
| Sample size | 24 |
| Population | Patients with major depressive disorder |
| Intervention | Psilocybin therapy |
| Duration | At least 4 weeks post-treatment |
| Topics | Neuroplasticity Psychedelic-assisted therapy |
| Keywords | Psilocybin therapy Psychedelic treatment Psilocybin treatment Mushroom therapy |
| Citations | 343 |
| Key finding | Psilocybin therapy increased cognitive flexibility for at least four weeks, but greater increases in neural flexibility between the ACC and PCC were associated with less improvement in cognitive flexibility. |
Abstract
Psilocybin has shown promise for the treatment of mood disorders, which are often accompanied by cognitive dysfunction including cognitive rigidity. Recent studies have proposed neuropsychoplastogenic effects as mechanisms underlying the enduring therapeutic effects of psilocybin. In an open-label study of 24 patients with major depressive disorder, we tested the enduring effects of psilocybin therapy on cognitive flexibility (perseverative errors on a set-shifting task), neural flexibility (dynamics of functional connectivity or dFC via functional magnetic resonance imaging), and neurometabolite concentrations (via magnetic resonance spectroscopy) in brain regions supporting cognitive flexibility and implicated in acute psilocybin effects (e.g., the anterior cingulate cortex, or ACC). Psilocybin therapy increased cognitive flexibility for at least 4 weeks post-treatment, though these improvements were not correlated with the previously reported antidepressant effects. One week after psilocybin therapy, glutamate and N-acetylaspartate concentrations were decreased in the ACC, and dFC was increased between the ACC and the posterior cingulate cortex (PCC). Surprisingly, greater increases in dFC between the ACC and PCC were associated with less improvement in cognitive flexibility after psilocybin therapy. Connectome-based predictive modeling demonstrated that baseline dFC emanating from the ACC predicted improvements in cognitive flexibility. In these models, greater baseline dFC was associated with better baseline cognitive flexibility but less improvement in cognitive flexibility. These findings suggest a nuanced relationship between cognitive and neural flexibility. Whereas some enduring increases in neural dynamics may allow for shifting out of a maladaptively rigid state, larger persisting increases in neural dynamics may be of less benefit to psilocybin therapy.